Across Europe, hopeful parents turned to a renowned sperm bank, trusting rigorous screening to keep future children safe.
For years, donations from one Danish man helped nearly 200 families have babies. Only later did doctors realise his sperm carried a rare genetic mutation linked to childhood cancers, raising sharp questions about how donor screening works.
A popular donor, nearly 200 children
Denmark has become a global hub for fertility treatment. The country hosts one of the largest sperm banks in the world, the European Sperm Bank, which ships samples to clinics across continents.
Between 2006 and 2022, an anonymous Danish donor, known publicly only by the pseudonym “Kjeld”, became one of its most widely used contributors. His sperm was distributed to 67 fertility clinics in 14 countries, according to Danish public broadcaster DR.
Those donations led to the birth of around 197 children worldwide. Almost half of them – 99 – were born in Denmark. For parents who had struggled with infertility, “Kjeld” represented a chance at the family they feared they might never have.
Over a 16-year period, one single donor helped create nearly 200 children, from Scandinavia to other parts of Europe and beyond.
Behind those statistics sit deeply personal stories: couples who had spent years in treatment, single women building families by choice, and LGBTQ+ parents relying on donor sperm to conceive.
First alarm: a child with cancer
The apparent success story began to shift in April 2020. The Danish sperm bank received a report that a child conceived with “Kjeld’s” sperm had been diagnosed with cancer. Genetic testing on the child identified a mutation, prompting concern that it might have come from the donor.
Initially, this could have looked like a tragic but isolated medical case. Childhood cancers, while rare, do occur, and a single cancer diagnosis does not automatically point to a donor problem.
Three years later, a second alert arrived. Another child, also conceived from the same donor, had developed cancer and was carrying a similar genetic mutation. With two independent, serious cases, suspicion hardened into a clear red flag.
➡️ What it reveals psychologically when you feel mentally busy in complete silence
➡️ Psychology explains what it means when someone constantly interrupts others
➡️ 5 psychological tricks to easily spot a bad person
➡️ After replacing 90% of his staff with AI, an Indian entrepreneur reports an unexpected outcome
➡️ Rushed to emergency surgery, she healed in just 24 hours thanks to a Coca-Cola treatment
The sperm bank ordered detailed genetic analyses of the donor’s stored samples. Those tests uncovered a mutation that had not been picked up during the original screening process.
Only after multiple children fell ill did in-depth testing reveal a rare TP53 mutation lurking in a portion of the donor’s sperm cells.
What is the TP53 gene and why does it matter?
Investigators found a mutation in the donor’s TP53 gene. This gene carries the instructions for making a protein called p53, one of the body’s key defences against cancer.
Often called the “guardian of the genome”, p53 constantly monitors DNA inside cells. When DNA damage is detected, p53 can pause cell division to allow time for repairs. If the damage is too severe, p53 can trigger the cell to self-destruct, preventing that damaged cell from multiplying into a tumour.
When TP53 is mutated, this protective system can fail. Faulty or missing p53 leaves damaged cells free to continue dividing, raising the risk that they turn into cancer. In some families, inherited TP53 mutations are linked to a condition called Li-Fraumeni syndrome, which dramatically increases the risk of a range of childhood and early adult cancers.
A rare and unusual mutation
In “Kjeld’s” case, the sperm bank stressed that this was not a classic inherited mutation present in every cell of his body. Instead, they described it as rare and previously undescribed.
According to the bank, the mutation appears to exist only in a fraction of his sperm cells. That means the donor himself does not show signs of disease and would likely pass standard health and genetic checks.
The TP53 mutation was found only in some of the donor’s sperm, not in his other cells, which may explain why screening initially missed it.
This type of situation is known as a “mosaic” mutation: a genetic change that arises during life, affecting only certain cells or tissues. In this case, the mutation likely occurred in the cells that give rise to sperm, rather than in the donor’s entire body.
As a result, not all of the almost 200 children conceived from his sperm will carry the mutation. The risk exists only for those embryos that happened to form from the affected sperm cells.
How did screening fail to spot it?
Sperm donors are typically screened for infectious diseases, general health conditions and, in many countries, a panel of common genetic disorders. But they are not routinely tested for every possible cancer-linked mutation, especially ones never seen before.
In this case, several factors likely contributed:
- The mutation was extremely rare and had not been documented in scientific literature.
- It affected only some sperm cells, making it harder to detect in standard blood or saliva tests.
- Existing donor screening protocols focus on known, frequent genetic disorders and clear personal or family history of disease.
Only when multiple children developed cancer and were genetically tested did the pattern emerge. Their results prompted targeted analysis of stored semen samples from the donor, which finally revealed the TP53 anomaly.
Global questions for fertility clinics
The case highlights a dilemma facing sperm banks and fertility regulators worldwide. Modern genetic technology can now identify an ever-growing catalogue of mutations, but broad screening raises cost, complexity and ethical issues.
This Danish case forces clinics and regulators to ask how far donor testing should go, and who bears responsibility when rare risks slip through.
Different countries set strict limits on how many births can come from a single donor, precisely to reduce the impact of any unforeseen medical issue. Yet with international shipment of sperm, one donor can still end up linked to dozens of clinics across multiple nations.
Some experts now argue for tighter global coordination, including:
- Lower caps on the number of families per donor.
- Central registries to track donor use across borders.
- Routine genetic re-evaluation if a child conceived with donor sperm develops a serious disease.
Infertility, donor sperm and risk perception
The episode lands in a context where infertility is common. In France, for instance, estimates from Inserm suggest that 15% to 25% of couples struggle to conceive after a year of unprotected intercourse. Similar proportions are seen in many high-income countries.
Those difficulties can come from ovulation disorders, blocked fallopian tubes or uterine problems in women. For men, low sperm count, hormonal issues, genetic abnormalities, varicocele and infections are frequent causes. Donor sperm becomes an option when treatments fail or when there is no male partner.
Parents turning to donors usually accept that medicine cannot guarantee zero risk. Even naturally conceived pregnancies carry chances of genetic disease or childhood cancer. Yet parents also reasonably expect that commercial or public sperm banks apply the highest feasible safety standards.
| Aspect | Natural conception | Donor conception |
|---|---|---|
| Knowledge of genetic background | Limited to family history | Health and genetic screening on donor |
| Screening for infections | Not systematic | Mandatory tests for donors |
| Risk of rare, unknown mutations | Present | Still present, though monitored after reports |
What this means for families and donors
For families already affected, the priority now lies in medical follow‑up, psychological support and, when appropriate, genetic counselling. Children conceived with the same donor may be offered testing for the TP53 mutation so that doctors can adapt surveillance for early signs of cancer.
For potential donors, the story underlines that participation in a sperm donation programme has long-term implications. Medical discoveries years later can lead to renewed testing, contact from clinics, or questions from offspring who may reach out as adults.
Key terms and practical implications
Several scientific terms in this case come with very concrete consequences for parents:
- TP53 mutation: A change in a gene that helps control cell division and cancer defence. Some variants raise cancer risk, especially in children and young adults.
- Mosaicism: When not all cells carry the same genetic change. Here, only some sperm carried the mutation, making the risk uneven among offspring.
- Genetic counselling: A medical service where specialists explain test results, estimate risks for relatives and discuss options such as enhanced screening or preventive measures.
Parents who used donor sperm and worry about similar scenarios can speak to their clinic or a genetics service. While this specific TP53 mutation appears unique to the Danish donor, the case illustrates how clinics respond when serious issues are reported: by investigating, tracing affected families and reviewing protocols.
The story also shows a shift in reproductive medicine. As sequencing technology becomes cheaper, some fertility centres may move towards broader genetic panels for donors. That could catch more problems early, but it may also raise the number of “variants of uncertain significance” that leave parents with more questions than answers.